It is the poor man’s GLP-1.

For a transcript of an episode of Hysteria, please email transcripts@crooked.com.

Political commentator and comedy writer Erin Ryan and former White House Deputy Chief of Staff Alyssa Mastromonaco are joined by a bicoastal squad of funny, opinionated women to talk through everything from reproductive rights to romcoms. They break down the political news of the week, plus the topics, trends, and cultural stories that affect women’s lives. New episodes drop every Thursday. Get in touch: hysteria@crooked.com.

Photos courtesy of AP Photo Archive

Crooked Media believes that we need a better conversation about politics, culture, and the world around us—one that doesn’t just focus on what’s broken, but what we can do to fix it. We are a media network that showcases stories, voices, and opportunities for activism that inform, entertain, and inspire action, because it’s up to all of us to do our part to build a better world.

That’s it. End of mission.

Learn more about us at crooked.com

The post This is SO GROSS appeared first on MASSIVE News.

For many people, the thought of a tasty burger or a cold pint of beer conjures up a vivid mental image and drives behaviour.

My own lab has shown this year that GLP-1 drugs reduce a type of activity in the lateral septum that may prevent it communicating so effectively with other brain regions.

Much more recent work has placed the lateral septum at the centre of a neural connectivity network. This has reframed how we think about its function.

Studies going back to the 1970s have linked vivid mental imagery with drug abuse.

One jump “upstream” from the dopamine-producing brain parts is a region called the lateral septum. This brain structure has been historically implicated in emotional regulation.

This region is well known as the place that lets us form long-term “episodic memories”. A famous case of hippocampal damage, Henry Molaison (patient HM), was unable to form new memories after his surgery for epilepsy. He effectively lived without a past, in permanent present tense.

These brain parts – the ventral tegmental area (VTA) and nucleus accumbens (NAc) – have been the subject of research on reward for decades. They are the obvious candidate regions to look for a mechanism for GLP-1 action in the brain. But they lack significant density of receptors for GLP-1 and are unlikely to be the direct mechanism.

These drugs are changing how we think about the brain’s reward system. They may also open new treatment options for obesity, alcohol dependence and the consumption of other addictive substances.

We must, therefore, consider other brain regions to understand the anti-consumption effect of GLP-1 drugs.

How the brain regulates reward stimuli

But for some, this process can malfunction. Preoccupation with these rewarding stimuli can lead to disorders of substance overuse, including overeating to the point of obesity and alcohol abuse.

As a side effect, people using these drugs also lost a lot of weight, in some cases almost as much as might be expected from bariatric surgery.

Emerging research points to this as the mechanism. GLP-1 activation directly in the lateral septum has recently been shown to reduce food consumption in mice. Earlier this year, another study showed the same for alcohol consumption.

This “where and when am I” information gets forwarded to the lateral septum. Key research has recently shown the lateral septum also contains place cells, but these cells strongly respond to rewards. They effectively add “what is good in this place” to the “where and when am I” information from the hippocampus.

There is one last reason to suspect the lateral septum as the mechanism behind the anti-consumption effect of GLP-1 agonists. It is absolutely loaded with GLP-1 receptors.

Critically, the lateral septum shares this information with the dopamine-producing regions we would normally associate with reward.

This link between thinking and doing serves a clear function – it motivates us to get the necessities for life.

The brain’s reward control centre

While a link between the lateral septum and another region called the hypothalamus is probably responsible for septal rage, the lateral septum links with many other regions with various functions.

The hippocampus also contains the remarkable “place cells” – neurons that fire corresponding to a person’s thoughts about their position in space and, as recent research has shown, time.

We have a reasonable understanding of the brain’s “reward circuitry” associated with regions that produce the neurotransmitter dopamine.

But there is another less well publicised effect. Human studies show that GLP-1 agonists reduce alcohol consumption. Preclinical animal studies suggest these drugs also reduce the use of cocaine, amphetamines, opiates and nicotine.

The lateral septum inherits much of its primary input from a brain region called the hippocampus.

Neuroscientists now think of the lateral septum as the brain region that lets us “think about” rewards – our conscious perception of them – and communicates with the machinery in the brain’s reward system that produces dopamine to make us feel good about them.

Understanding this link between craving and consuming is central to understanding addiction. This has eluded neuroscience for decades, but the introduction of a new class of drugs for weight loss may have given us just the lever we need to understand it.

Back in 1953, pioneering US behavioural researchers Joseph Brady and Walle Nauta coined the term “septal rage” when animals with damage in the lateral septum showed increased aggression, while direct stimulation of this brain region reduced aggression.

These findings are reshaping our understanding of how the brain processes rewards and have put the spotlight firmly on the lateral septum as the home of cravings.

These new drugs – including Ozempic and Wegovy – mimic the GLP-1 hormone to stimulate insulin release, slow digestion, and increase feelings of fullness. They are known as GLP-1 agonists and were originally used to treat type 2 diabetes because they help control blood sugar.

The post Weight-loss drugs like Ozempic could work for addiction too – and we finally know how appeared first on MASSIVE News.

India just hit a massive turning point in the fight against obesity and diabetes. As of March 21, 2026, the patent on Semaglutide—the magic ingredient in Ozempic and Wegovy—has officially expired.

For years, Novo Nordisk held the “keys to the kingdom,” with weight-loss treatments costing up to ₹27,000 a month. But the game has changed. Indian drugmakers are now launching generic versions that could bring costs down to just ₹3,000. In this video, we break down how these GLP-1 receptor agonists work, which Indian companies are leading the “first-mover” race, and why experts are worried about the “cosmetic misuse” of these medical miracle drugs.

Highlights of the video:

The End of the Semaglutide Monopoly
What is Semaglutide? How GLP-1 Works
Massive Price Drop: ₹27,000 to ₹3,000?
The Generic Race: Sun Pharma, Cipla & Dr. Reddy’s
The Benefits: Democratizing Metabolic Health
The Dark Side: Misuse and Quality Concerns
India: The Global Model for Affordable Care

#semaglutide #ozempicIndia #weightlossdrug #semaglutideIndia #ObesityCrisis #healthnewsIndia #diabetesCare

Welcome to The Free Press Journal – Trusted News Since 1928
Delivering reliable, unbiased, and in-depth journalism for over 96 years. Stay informed with the latest in breaking news, politics, business, entertainment, sports, health, and more—straight from one of Mumbai’s oldest and most respected English dailies.

📲 Subscribe for real news, real stories, and real impact.

#FreePressJournal #FPJ #BreakingNews #IndiaNews #TrustedJournalism

Subscribe To Our Channels:
Website: https://www.freepressjournal.in
Social Media Links
Facebook: https://www.facebook.com/freepressjournal
YouTube: https://www.youtube.com/@TheFreePressJournal
YouTube Shorts: https://www.youtube.com/@TheFreePressJournal/shorts
Twitter: https://x.com/fpjindia
Instagram: https://www.instagram.com/freepressjournal
Telegram: https://t.me/freepressjournal
Follow The Free Press Journal Channel On WhatsApp
The Free Press Journal E-Paper Is Now Available On Your Android Phones & Tablets At No Cost To Download The App: https://www.freepressjournal.in/get-apps

The post Cipla, Sun Pharma & Dr Reddy’s Join the Weight Loss Race| Diabetes & Obesity Drugs Get Cheaper. appeared first on MASSIVE News.